Incannex files registration statement with the SEC for proposed initial public offering in the United States
Incannex Psi-GAD clinical development overview
Incannex submits HREC proposal and FDA pre-IND meeting request for Psi-GAD psilocybin therapy for Generalised Anxiety Disorder
We wish to draw your attention to an announcement and presentation released by Incannex (ASX:IHL) this week. The company has… Read more
Incannex Files Patent for IHL-42X for Obstructive Sleep Apnoea
Incannex (IHL) has this morning announced that it has filed an International Patent Application entitled “Methods for the treatment of… Read more
IHL : Incannex engages Procaps to develop and manufacture IHL-675A soft-gel capsules in preparation for clinical trials
CEO and Managing Director of Incannex Healthcare, Mr Joel Latham, said; “Procaps offers Incannex a complete supply chain solution for… Read more
Incannex to develop IHL-216A formulation for use in pivotal clinical trials required for product registration
Vectura is a state-of-the-art contract development and manufacturing organisation (CDMO) that specialises in the development and manufacture of inhaled drugs… Read more
Incannex partners with the UWA Centre for Sleep Science to uprate the IHL-42X clinical trial to a multi-site study
Four in 10 Australian adults experience regular poor sleep, the consequences of which can have significant impacts on health, performance,… Read more
Incannex: Positive pre-IND meeting with US FDA
Following guidance from FDA, Incannex is delighted to report that it will expand its development program to assesses the potential… Read more